Boehringer Ingelheim launches three phase III trials in precision Oncology
Boehringer Ingelheim has initiated three Phase III clinical trials aimed at advancing…
WHO Releases First-Ever Guidance to Advance Child-Focused Dengue Treatments
WHO has released its first-ever guidance to accelerate the development of child-focused…
Vertex Presents New CASGEVY Data in Children, Expands Global Regulatory Filings
Vertex Pharmaceuticals presented new data showing positive outcomes with CASGEVY in children…
UAE Approves New Oral Breast Cancer Treatment for Hormone-Resistant Cases
The UAE has approved AstraZeneca’s Etcamah, a new oral therapy for advanced…
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
FDA approves Lilly’s EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
The U.S. FDA has approved a new maintenance dosing regimen for Eli…
Harbour BioMed Announces NMPA Acceptance for the Treatment of Advanced Solid Tumors
Harbour BioMed has announced that China’s National Medical Products Administration (NMPA) has…
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Antag Therapeutics has appointed obesity treatment expert Philip Just Larsen as Chief…
London Biotechnology Show 2026
London Biotechnology Show 2026 will unite global biotech leaders, pharmaceutical companies, investors,…
Boston Scientific Announces Strategic Investment in MiRus LLC
Boston Scientific announced a $1.5 billion investment in MiRus LLC to support…
